Anadys, Novartis Pull Plug On Toll-Like Receptor Candidate
Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.
Decision does not affect agreement with Novartis to develop TLR7 agonists for hepatitis C and B and other infectious diseases, Anadys CEO tells “The Pink Sheet” DAILY.